Bosnalijek makes a Net Profit of 2 Million BAM

In 2014, after a difficult business year and struggle for its existence, Bosnalijek d.d. (Bosnalijek), the largest pharmaceutical company in Bosnia and Herzegovina, stabilised its business operations and recorded a profit gain.


Bosnalijek makes a Net Profit of 2 Million BAM
The acting Manager of Bosnalijek, Nedim Uzunović, stressed, “Along with our new business direction, aimed at achieving business results, the management had to make corrections to the financial reports from the previous years in order to present a reliable and realistic financial report to our shareholders and all interested parties.”

In order to achieve a so-called ‘clean start’ for the period from 2011 to 2013 Bosnalijek engaged an international auditing company to examine and audit the company’s financial reports and records. In accordance with the resulting report, all company reports were subsequently adjusted and all identified errors and irregularities eliminated prior to being sent to the Agency for Financial, Information and Mediation Services (AFIP).

The entire process was performed in accordance with valid regulations and international accounting standards. The resulting adjustments led to a reduction in capital to the total amount of 9,299,677 BAM, down from 136,317,326 BAM to 127,017,649 BAM. The highest amount of 8,003,619 BAM relates to 2011, while the reductions in 2012 and 2013 amounted to 388,957 BAM and 907,101 BAM respectively.

The identified errors in the financial reports and record that gave rise to suspicion of criminal offences shall duly be reported to the relevant authorities and criminal reports filed against the individuals responsible.

The independent auditing company Deloitte d.o.o., elected at the shareholders assembly meeting held on 23 May 2014, stated in its report that, after corrections, the company’s financial report for 2013 presented the financial situation objectively in all material respects.

The finalised ‘clean start’ has allowed Bosnalijek to continue its business operations based on reliable information and to develop its business plan objectively for the upcoming period.

The result of the responsible actions and successful business strategy adopted by the new management was evident in the first three months of 2014: Bosnalijek made a net profit of 2 million BAM compared to the same period last year, when the company made a loss of 1.4 million BAM.

The company now has many reasons to be optimistic, especially when you take into account the extraordinary business difficulties it experienced in the previous year. The company management is certain that the upcoming six monthly results will show an additional increase in profit and further confirm stabilisation and business growth.
June 18, 2014
Previous news
Financial News
Reports   
Other information   
novembar 21. 2024 |
SASE |
BSNLR - Bosnalijek d.d. Sarajevo: 12,47 3,89%
ABOUT US Company Profile Corporate Responsibility Bosnalijek in the World
PRODUCTS
Search products by trade name Search products by generic name
INVESTORS Quarterly Reports Audit Report Financial News Shareholders’ Meeting Useful Links
PRESS CENTRE News Press Kit Corporate and Visual Identity Video Gallery Photo Gallery Media Contact
CAREER Career with Bosnalijek Principles and Values How is it to work at Bosnalijek? Employment Vacancies Contact Information
OUR PAGES Royal Jelly® Alerix® Enterofuryl STOP® Rhinostop® Lysobact® Fenix NEO® Lynase® Rhinostop® HOT MECOBALAMIN D3 SPRAY® DOLOREX® Lysoderm® Oralni mukozitis